BharatNotes What is Vaccine Diplomacy?
Vaccine diplomacy is the strategic use of vaccines — their research, manufacture, donation, sale and distribution — to pursue a nation's foreign-policy and soft-power goals. It is a sub-field of global health diplomacy in which life-saving medical goods become instruments of goodwill, influence and geopolitical positioning. The term gained global currency during the COVID-19 pandemic, when access to vaccines became a strategic resource and major powers competed to supply them to lower-income nations.
India's Vaccine Maitri Initiative
India's flagship effort, Vaccine Maitri ("Vaccine Friendship"), was launched on 20 January 2021, just four days after India began its own domestic vaccination drive. Reflecting the "Neighbourhood First" policy, Bhutan and the Maldives were the first countries to receive Indian-made vaccines as grants, followed quickly by Nepal, Bangladesh, Myanmar and Seychelles. Supplies were delivered through three channels — grants, commercial sales, and the COVAX facility — leveraging India's status as a leading global vaccine manufacturer (notably the Serum Institute of India's "Covishield").
Exports were paused from around April 2021 as the severe Delta-driven second wave forced India to prioritise domestic vaccination, before resuming later that year. Figures vary by reporting date: by 21 February 2022, India had supplied roughly 16.3 crore (163 million) doses to about 96 countries, split across grant, commercial and COVAX routes (PIB/MEA data, as of Feb 2022).
Major Players and Mechanisms
| Actor / Mechanism | Key feature | Status (as of 2023-24) |
|---|---|---|
| India — Vaccine Maitri | Grants + commercial + COVAX; Neighbourhood First | Launched 20 Jan 2021; ~163 mn doses to ~96 countries (Feb 2022) |
| China | "Health Silk Road"; Sinopharm, Sinovac to Global South | Large bilateral supplier, esp. Asia, Africa, Latin America |
| Russia | Sputnik V; emphasis on early roll-out abroad | Marketed widely across many countries |
| COVAX | WHO + GAVI + CEPI + UNICEF co-led equity facility | Closed 31 Dec 2023; ~2 billion doses to 146 economies |
| Quad Vaccine Partnership | US-India-Japan-Australia; India as manufacturing hub | Launched Mar 2021; target 1.2 bn doses (Indo-Pacific) |
Significance and Critique
Vaccine diplomacy enhanced India's image as the "pharmacy of the world" and strengthened ties across the Global South, while countering China's expanding health-sector influence. The Quad Vaccine Partnership (announced March 2021) channelled a US Development Finance Corporation loan to Indian manufacturer Biological E, though production and export-ban setbacks meant its one-billion-dose goal fell short. Multilateral equity efforts like COVAX sought to counter "vaccine nationalism," whereby richer nations hoarded supplies.
Critics note the tension between humanitarian branding and domestic needs — India's 2021 export halt during its second wave drew scrutiny — and warn that vaccine diplomacy can deepen dependence or be transactional. Nonetheless, it cemented health security as a permanent axis of statecraft.
UPSC Angle
For Mains GS2, frame this around soft power, Neighbourhood First, India-China competition in the Global South, and India's role in reforming global health governance. For GS3, connect it to indigenous vaccine R&D, manufacturing capacity, and pandemic preparedness. A balanced answer should weigh strategic gains against the ethics of prioritising exports over domestic coverage.
